This multi-center study was designed as a trial to explore the frequency of silent hepatitis B infection among hepatitis C patients and to determine the prevalent genotype of hepatitis C virus (HCV) 
INTRODUCTION
Hepatitis C virus is the major etiological agent of chronic hepatitis and liver disease worldwide, and it is a major cause of morbidity and mortality. In 80% of cases, infection with HCV results in chronic hepatitis, possibly leading to cirrhosis and hepatocellular carcinoma [1] . HCV is characterized by a high degree of nucleotide sequence variability. Overall, the heterogeneity of the viral genome ranges from 30 to 35% between different genotypes, although it varies with the specific region of the genome, and it has been used to define three types of regions: highly conserved regions, e.g., the 5′ untranslated region, variable regions, e.g., envelope 1
[E1] and nonstructural 5b
[NS5b] and hypervariable regions (HVR), e.g., HVR1 and HVR2 in E2
[2] . Furthermore, because of errors of the RNA-dependent RNA polymerase, HCV has a high rate of mutation during replication, and it exists in the bloodstreams of infected persons as complex distributions of mutants known as viral quasi-species, which fluctuate during the course of the disease, mainly as a result of immune pressure. These coexisting mutant genomes always have a consensus, or master, sequence [3] . The classification HCV into six major genotypes has been accepted
and there is further intra-subtype and intra-subject heterogeneity [5] . The development of an effective HCV vaccine to protect humans from HCV infection and chronic liver disease is a public health priority, yet differences in antigenic epitopes in genotypes, subtypes, and quasi-species could make cross-protection unlikely [6] . HCV genotypes 4-6 are very common in geographic areas where chronic hepatitis C is highly prevalent. In Africa, circulating HCV is extremely heterogeneous [4] . Genotype 5 is endemic in Southern Africa. Genotype 1 circulates in North and Central Africa, and Genotype 2 has been found in North, Western, and Central Africa [7] . HCV Genotypes 1 and 4 are very heterogeneous in Cameroon, perhaps due to ancient infections. The homogeneity of HCV Genotype 2 indicates its more recent introduction from Western Africa [8] . . Occult hepatitis B has been strongly implicated as a culprit that facilitates the development of hepatocellular carcinoma, typically in the background of cirrhosis. The finding of occult hepatitis B in noncirrhotic hepatocellular carcinomas among patients with hepatitis C who achieved antiviral sustained virologic response raises provocative theories regarding the natural history of both of these viral hepatitis agents
[11] . The present study was designed as a trial to explore the frequency of silent hepatitis B infection among hepatitis C patients and to determine the prevalent genotype of hepatitis C virus in these patients. .
PATIENTS & METHODS

Statistical analysis
Obtained data were presented as mean±SD, ranges, numbers and ratios. Results were analyzed using paired ttest and Chi-square test. Possible relationships were investigated using Pearson linear regression. Sensitivity and specificity of determination of HCV genotype and detection of silent hepatitis B as predictors of severe hepatitis were evaluated and confirmed using the receiver operating characteristic (ROC) curve analysis judged by the area under the curve (AUC). Statistical analysis was conducted using the SPSS (Version 10, 2002) for Windows statistical package. P value <0.05 was considered statistically significant.
RESULTS
Estimated liver function tests showed a significant (p<0.05) difference between patients included in the three studied classes, being worse in patients of Class C, ( Table  2) .
The HCV-Ab were detected in all samples irrespective of its severity class and qualitative PCR identified HCV-RNA (Fig. 1 (Fig. 2) .
The HBV DNA (Fig. 3) were detected using qualitative PCR in 20 samples (44.4%); of these 20 samples of silent hepatitis B, 4 samples belong to class A patients, 7 samples belong to class B patients and 9 samples were of class C. There was a significant increase of the frequency of silent HB in patients with class B (X 2 =5.446, p<0.01) and C (X 2 =8.154, p<0.001) in comparison to frequency detected in class A patients with a non-significant difference between classes B and C (X 2 =0.174, p>0.05), (Fig. 4) (Fig. 7) . There was positive but nonsignificant correlation between both HCV genotype and the presence of silent hepatitis B infection and patients' age or gender or clinical severity class. However, using ROC curve analysis to evaluate the sensitivity and specificity of detection of silent hepatitis B infection and identification of HCV genotype as predictors of severe hepatitis showed a non-specific role for genotyping in prediction of severity with AUC=0.467, while the detection of HBV DNA using PCR in patients with HCV infection is a specific predictor of severity with AUC=0.617, (Fig. 8) . . The current study was designed as a trial to explore the frequency of silent hepatitis B infection among hepatitis C patients and to determine the incidence genotype of hepatitis C virus in these patients
The HBV DNA was detected in 20 samples (44.4%), such frequency of silent hepatitis B infection in HCV cirrhotic patients with HBsAg negative goes in hand with the previously reported results in literature. Georgiadou et al. [26] investigated HCV patients for the presence of occult HBV in an attempt to determine the frequency and importance of this phenomenon and reported that HBV-DNA was detected in 26.2% of HCV-infected patients and HBV-DNA was neither associated with HBV markers, nor with epidemiological and virologic data and concluded that one quarter of HCV-infected patients had occult HBV infection.
Ghisetti et al.
[27] reported a frequency rate of occult hepatitis B of 64% in HCV patients who were HBsAg negative and undergoing transplantation surgery. Fujiwara et al.
[28] reported that hepatitis B virus DNA was amplified in 19.5% of the HCV-related chronic liver disease.
Honarkar et al.
[29] detected hepatitis B virus-DNA in 22% of chronic liver disease patients and Datta et al. [30] reported occult HBV in 53.6% of 28 HBSAg negative samples. These different figures could be attributed to several factors; patients from countries highly endemic for HBV are more likely to develop occult HBV infections, the nature of biological material tested, with a higher proportion for liver compared to serum specimen and the method of detection, including PCR primer selection.
On contrary to the obtained results; Khattab et al. [31] assessed the prevalence and clinical consequences of occult HBV infection in chronic hepatitis C patients undergoing antiviral therapy and found occult HBV genomes were in the serum of four of 53 (7.5%) patients, unrelated to anti-HBc status and concluded that the prevalence of occult HBV coinfection among patients with chronic hepatitis C was low and independent of the presence of markers of previous HBV infection. These low figures could be attributed to the effect of antiviral therapy; in agreement with this attribution, Hasegawa et al. [32] who found that occult HBV may be sensitive to interferon (INF) therapy although HBV is not completely eradicated
The ROC curve analysis showed that presence of occult HB infection could be a specific predictor of severe liver derangement despite the positive non-significant correlation with clinical class of severity of liver disease. That finding agreed with Pollicino et al. [33] who reported that occult HBV is a risk factor for development of hepatocellular carcinoma and the potential mechanisms whereby overt HBV might induce tumor formation are mostly maintained in cases of occult infection. Raimondo et al. [34] reported that coinfection by HBV and HCV may have considerable clinical relevance and is generally believed to be a factor favoring the progression of liver fibrosis toward cirrhosis and the development of liver cancer.
Genotyping of HCV reported 41 samples (91.1%) with genotype-4 and 4 samples (8.9%) with genotype-1; these figures agreed with that reported by Elsaway et al. [35] who reported HCV genotype 4 in 91% of samples of their series collected from Dakahlia provinces, and with Genovese et al. [36] who reported that only HCV genotype 4 was isolated from patients with chronic liver disease in Alexandria District and the other previously determined genotypes were variants of genotype 4 due to its heterogeneity. Also, Derbala et al. [37] reported that Egypt has a high prevalence rate of hepatitis C infection and as much as 90% is genotype 4 and the poor response of genotype 4 in Egypt to different forms of IFN therapies may be related to an intrinsic resistance to the direct antiviral effect of IFN.
It could be concluded that HCV genotype-4 is the most prevalent type in Egyptian Hepatitis C cirrhotic patients with a prevalence of silent hepatitis B of 44.4% and its detection is a specific predictor of severe cirrhosis. 
